NASDAQ: AGIOAgios Pharmaceuticals Inc Stock
$29.43+0.40 (+1.38%)
Updated Apr 18, 2024
AGIO Price
$29.43
Fair Value Price
-$8.50
Market Cap
$1.65B
52 Week Low
$19.80
52 Week High
$35.50
P/E
-4.65x
P/B
2.04x
P/S
46.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$26.82M
Earnings
-$352.09M
Gross Margin
89.3%
Operating Margin
-1,312.63%
Profit Margin
-1,312.6%
Debt to Equity
0.16
Operating Cash Flow
-$296M
Beta
1.07
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AGIO Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGIO ($29.43) is overvalued by 446.29% relative to our estimate of its Fair Value price of -$8.50 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AGIO ($29.43) is not significantly undervalued (446.29%) relative to our estimate of its Fair Value price of -$8.50 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AGIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AGIO due diligence checks available for Premium users.
Be the first to know about important AGIO news, forecast changes, insider trades & much more!
AGIO News
Valuation
AGIO fair value
Fair Value of AGIO stock based on Discounted Cash Flow (DCF)
Price
$29.43
Fair Value
-$8.50
Undervalued by
446.29%
AGIO ($29.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AGIO ($29.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AGIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AGIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.65x
Industry
15.68x
Market
41.33x
AGIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.04x
Industry
5.76x
AGIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AGIO's financial health
Profit margin
Revenue
$7.1M
Net Income
-$95.9M
Profit Margin
-1,350.7%
AGIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AGIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$937.1M
Liabilities
$126.1M
Debt to equity
0.16
AGIO's short-term assets ($833.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGIO's short-term assets ($833.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$72.5M
Investing
$95.5M
Financing
$847.0k
AGIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGIO vs Biotech Stocks
Agios Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.